nodes	percent_of_prediction	percent_of_DWPC	metapath
Frovatriptan—HTR1D—Serotonin receptors—HTR2A—conduct disorder	0.0697	0.0697	CbGpPWpGaD
Frovatriptan—HTR1B—Serotonin receptors—HTR2A—conduct disorder	0.0683	0.0683	CbGpPWpGaD
Frovatriptan—HTR1A—Serotonin receptors—HTR2A—conduct disorder	0.052	0.052	CbGpPWpGaD
Frovatriptan—HTR1D—Monoamine GPCRs—DRD4—conduct disorder	0.0476	0.0476	CbGpPWpGaD
Frovatriptan—HTR1B—Monoamine GPCRs—DRD4—conduct disorder	0.0466	0.0466	CbGpPWpGaD
Frovatriptan—HTR1D—Amine ligand-binding receptors—DRD4—conduct disorder	0.04	0.04	CbGpPWpGaD
Frovatriptan—HTR1B—Amine ligand-binding receptors—DRD4—conduct disorder	0.0392	0.0392	CbGpPWpGaD
Frovatriptan—HTR1A—Monoamine GPCRs—DRD4—conduct disorder	0.0355	0.0355	CbGpPWpGaD
Frovatriptan—CYP1A2—Methylation—COMT—conduct disorder	0.0323	0.0323	CbGpPWpGaD
Frovatriptan—HTR1D—Monoamine GPCRs—HTR2A—conduct disorder	0.031	0.031	CbGpPWpGaD
Frovatriptan—HTR1B—Monoamine GPCRs—HTR2A—conduct disorder	0.0304	0.0304	CbGpPWpGaD
Frovatriptan—HTR1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.0298	0.0298	CbGpPWpGaD
Frovatriptan—HTR1D—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0261	0.0261	CbGpPWpGaD
Frovatriptan—HTR1B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0256	0.0256	CbGpPWpGaD
Frovatriptan—HTR1A—Monoamine GPCRs—HTR2A—conduct disorder	0.0232	0.0232	CbGpPWpGaD
Frovatriptan—CYP1A2—Estrogen metabolism—COMT—conduct disorder	0.0202	0.0202	CbGpPWpGaD
Frovatriptan—HTR1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0195	0.0195	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.014	0.014	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0138	0.0138	CbGpPWpGaD
Frovatriptan—CYP1A2—Melatonin metabolism and effects—MAOA—conduct disorder	0.0137	0.0137	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.0109	0.0109	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—CGA—conduct disorder	0.0107	0.0107	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0105	0.0105	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—CGA—conduct disorder	0.0105	0.0105	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—DRD4—conduct disorder	0.00989	0.00989	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—DRD4—conduct disorder	0.00969	0.00969	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00918	0.00918	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00899	0.00899	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.0082	0.0082	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CGA—conduct disorder	0.00798	0.00798	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00787	0.00787	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0077	0.0077	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—DRD4—conduct disorder	0.00738	0.00738	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00685	0.00685	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00668	0.00668	CbGpPWpGaD
Frovatriptan—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00619	0.00619	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—CGA—conduct disorder	0.00605	0.00605	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00599	0.00599	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—DRD4—conduct disorder	0.00599	0.00599	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—CGA—conduct disorder	0.00592	0.00592	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00587	0.00587	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00587	0.00587	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—DRD4—conduct disorder	0.00587	0.00587	CbGpPWpGaD
Frovatriptan—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.00566	0.00566	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CGA—conduct disorder	0.00549	0.00549	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CGA—conduct disorder	0.00538	0.00538	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00513	0.00513	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00503	0.00503	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CGA—conduct disorder	0.00451	0.00451	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00447	0.00447	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—DRD4—conduct disorder	0.00447	0.00447	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CGA—conduct disorder	0.00409	0.00409	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00408	0.00408	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00408	0.00408	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—HTR2A—conduct disorder	0.00391	0.00391	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00383	0.00383	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—HTR2A—conduct disorder	0.00383	0.00383	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00354	0.00354	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—DRD4—conduct disorder	0.00339	0.00339	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—DRD4—conduct disorder	0.00331	0.00331	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—COMT—conduct disorder	0.00331	0.00331	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.00329	0.00329	CbGpPWpGaD
Frovatriptan—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.00327	0.00327	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CGA—conduct disorder	0.00324	0.00324	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CGA—conduct disorder	0.00318	0.00318	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—DRD4—conduct disorder	0.00307	0.00307	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—DRD4—conduct disorder	0.00301	0.00301	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—HTR2A—conduct disorder	0.00292	0.00292	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00282	0.00282	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—WASF1—conduct disorder	0.0026	0.0026	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—WASF1—conduct disorder	0.00254	0.00254	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—DRD4—conduct disorder	0.00253	0.00253	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CGA—conduct disorder	0.00242	0.00242	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—DRD4—conduct disorder	0.00229	0.00229	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—HTR2A—conduct disorder	0.00221	0.00221	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—HTR2A—conduct disorder	0.00216	0.00216	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—HTR2A—conduct disorder	0.00201	0.00201	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—HTR2A—conduct disorder	0.00196	0.00196	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—WASF1—conduct disorder	0.00194	0.00194	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—DRD4—conduct disorder	0.00182	0.00182	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—DRD4—conduct disorder	0.00178	0.00178	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—HTR2A—conduct disorder	0.00165	0.00165	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—HTR2A—conduct disorder	0.0015	0.0015	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—DRD4—conduct disorder	0.00135	0.00135	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CGA—conduct disorder	0.00126	0.00126	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—HTR2A—conduct disorder	0.00118	0.00118	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—HTR2A—conduct disorder	0.00116	0.00116	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—HTR2A—conduct disorder	0.000884	0.000884	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—EP300—conduct disorder	0.000628	0.000628	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—EP300—conduct disorder	0.000615	0.000615	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—COMT—conduct disorder	0.000567	0.000567	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—MAOA—conduct disorder	0.000563	0.000563	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000546	0.000546	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—EP300—conduct disorder	0.000468	0.000468	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—EP300—conduct disorder	0.000243	0.000243	CbGpPWpGaD
